Contributions
Abstract: EP1563
Type: ePoster
Abstract Category: Therapy - symptomatic - Treatment of specific symptoms
Introduction: Recurrent urinary tract infections (rUTIs) are a significant problem in people with multiple sclerosis (PwMS). Current therapeutic options are limited. D-mannose is a natural food supplement which has been shown to prevent UTIs in women, however benefits in PwMS are unknown. This study assessed D-Mannose feasibility in PwMS reporting rUTIs.
Methods : A prospective single centre, open-label, feasibility study with PwMS suffering rUTIs (≥3/year or ≥2 in preceding 6 months). Participants took D-mannose-powder 1.5 grams bd (16-weeks) and monitored suspected UTIs using urine dipsticks. Diaries were used to record compliance, number of antibiotic prescriptions, dipstick results cultures.
Results: 22 PwMS (18 female, 4 men), median age 50 years (46-59) were enrolled. 61 suspected-UTI episodes were recorded; 19/61 (31.1%) were confirmed UTIs; 29 (47.5%) antibiotic prescriptions were written. Number of proven-UTIs decreased both in catheter users and non-users (p< 0.01). No side effects or adverse effects were reported.
Discussion: This study demonstrates the feasibility of using D-mannose in PwMS experiencing recurrent UTIs and self-monitoring for infections, without any safety concerns. The use of D-mannose was associated with a reduction in the number of UTIs. As the study was designed to evaluate only feasibility, no conclusions could be drawn about efficacy, however the results are encouraging and clearly, a randomized controlled study designed to evaluate efficacy is required. The emerging global problem of antimicrobial resistance makes agents such as D-Mannose a particularly attractive option for the prophylaxis against rUTIs.
Disclosure: Mahreen Pakzad: Has been a speaker for Astellas and Medtronic, but nil relevant to this study.
Jalesh Panicker: None relevant to this study
Veronique Phe: None relevant to this study
Bernadette Porter: None relevant to this study
Jeremy Chataway: None relevant to this study
Carmel Curtis: None relevant to this study
Abstract: EP1563
Type: ePoster
Abstract Category: Therapy - symptomatic - Treatment of specific symptoms
Introduction: Recurrent urinary tract infections (rUTIs) are a significant problem in people with multiple sclerosis (PwMS). Current therapeutic options are limited. D-mannose is a natural food supplement which has been shown to prevent UTIs in women, however benefits in PwMS are unknown. This study assessed D-Mannose feasibility in PwMS reporting rUTIs.
Methods : A prospective single centre, open-label, feasibility study with PwMS suffering rUTIs (≥3/year or ≥2 in preceding 6 months). Participants took D-mannose-powder 1.5 grams bd (16-weeks) and monitored suspected UTIs using urine dipsticks. Diaries were used to record compliance, number of antibiotic prescriptions, dipstick results cultures.
Results: 22 PwMS (18 female, 4 men), median age 50 years (46-59) were enrolled. 61 suspected-UTI episodes were recorded; 19/61 (31.1%) were confirmed UTIs; 29 (47.5%) antibiotic prescriptions were written. Number of proven-UTIs decreased both in catheter users and non-users (p< 0.01). No side effects or adverse effects were reported.
Discussion: This study demonstrates the feasibility of using D-mannose in PwMS experiencing recurrent UTIs and self-monitoring for infections, without any safety concerns. The use of D-mannose was associated with a reduction in the number of UTIs. As the study was designed to evaluate only feasibility, no conclusions could be drawn about efficacy, however the results are encouraging and clearly, a randomized controlled study designed to evaluate efficacy is required. The emerging global problem of antimicrobial resistance makes agents such as D-Mannose a particularly attractive option for the prophylaxis against rUTIs.
Disclosure: Mahreen Pakzad: Has been a speaker for Astellas and Medtronic, but nil relevant to this study.
Jalesh Panicker: None relevant to this study
Veronique Phe: None relevant to this study
Bernadette Porter: None relevant to this study
Jeremy Chataway: None relevant to this study
Carmel Curtis: None relevant to this study